Comparison between two antiemetics (ondansetron and ramosetron) in the prevention of Post operative nausea and vomiting

Comparison of ramosetron and ondansetronf for prevention of early and delayed Post operative nausea and vomiting following craniotomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/01/011345

Enrollment

130

Registered

2018-01-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C719- Malignant neoplasm of brain, unspecified Health Condition 2: null- The patients undergoing Craniotomy(Intra-cranial neoplasm, Traumatic brain Injury)were assessed for Post-Operative Nausea and Vomiting for 48 Hours

Interventions

Intervention1: Injection Ramosetron: The efficacy and side effects of Injection Ramosetron for the prevention of post-operative nausea and vomiting was assessed for 48 hours postoperatively for patien

Eligibility

Inclusion criteria

Inclusion criteria: 1.ASA I & II patients. 2.Mallampatti grades I & II.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of motion sickness, Gastroesophageal Reflux Disease (GERD). 2.Patients with major Cardiovascular Disease, Respiratory Disease and uncontrolled diabetes mellitus. 3.Patients with anticipated difficult intubation. 4.History of alcohol, drug abuse or smokers. 5.Post operative Glasgow Coma Score (GCS) less than 8.

Design outcomes

Primary

Measure	Time frame
- POST OPERATIVE NAUSEA AND VOMITING. Timepoint: -NAUSEA VOMITING RETCHING	—

Secondary

Measure	Time frame
SIDE EFFECTS OF DRUGS USEDTimepoint: Dizziness Headache Dyspepsia Weakness Flushing Urticaria	—

Countries

India

Contacts

Public ContactObaid Ahmad Siddiqui

Jawaharlal Nehru Medical College,AMU

obaidahmad2008@gmail.com9897695761

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026